BRD4
ENSG00000141867
Target class
Epigenetic regulator
Chromosome
19
Approved drugs
0
Clinical candidates (approved and in development)
6
- Approved drugs
- 0
- ClinGen gene-disease validity
- Definitive
- Clinical candidates (approved and in development)
- 6
- Chemical probe available
- Yes
- Target name
- BRD4
- Gene name
- Bromodomain containing 4
- Gene symbol
- BRD4
- Protein name
- Bromodomain-containing protein 4 (Protein HUNK1)
- HUNKI
- MCAP
- CAP
- HUNK1
- FSHRG4
- Gene biotype
- Protein coding
- Gene family
- Bromodomain and extra-terminal domain family|Bromodomain containing
- Target class
- Epigenetic regulator
- Target type
- Human gene
- Tissues expressed in
- 54
- Protein localisation evidence grade
- Enhanced
- Highest tissue expression
- 39.4
- Tissue specificity (Gini)
- 0.248
- Tissue specificity (tau)
- 0.414
- KEGG gene identifiers
- hsa:23476
- Protein interaction confidence
- 0.835946
- Protein interaction partners
- 129
- R-HSA-9679191
- R-HSA-9909649
- End position
- 15332545
- Start position
- 15235519
- Chromosome
- 19
- Strand
- Reverse
- Nucleus . Chromosome . Note=Associates with acetylated chromatin (PubMed:16109376, PubMed:21890894). Released from chromatin upon deacetylation of histones that can be triggered by different signals such as activation of the JNK pathway or nocodazole treatment (PubMed:16109376, PubMed:21890894). Preferentially localizes to mitotic chromosomes, while it does not localize to meiotic chromosomes (PubMed:16109376, PubMed:21890894). .
- SUBCELLULAR LOCATION: [Isoform B]: Chromosome .
- Mitotic chromosome
- Nucleoplasm
- PubMed 16109376
- PubMed 25593309
- PubMed 21890894
- PubMed 23728299
- Tissue specificity (tau)
- 0.414362
- Expression inequality (Gini)
- 0.247809
Expression in transcripts per million
- Uterus
- 39.4
- Artery - Tibial
- 38.87
- Cervix - Endocervix
- 38.51
- Ovary
- 38.44
- Cervix - Ectocervix
- 37.5
Expression in transcripts per million
- Uterus39.4
- Artery - Tibial38.87
- Cervix - Endocervix38.51
- Ovary38.44
- Cervix - Ectocervix37.5
- Skin - Sun Exposed (Lower leg)36.09
- Skin - Not Sun Exposed (Suprapubic)34.98
- Testis34.69
- Artery - Aorta34.51
- Nerve - Tibial34.48
- Lung34.43
- Vagina32.98
- Fallopian Tube32.77
- Thyroid32.69
- Artery - Coronary31.26
- Spleen30.85
- Prostate29.83
- Brain - Cerebellum29.66
- Bladder28.62
- Cells - EBV-transformed lymphocytes28.21
- Colon - Sigmoid28.19
- Breast - Mammary Tissue28.1
- Adipose - Subcutaneous27.58
- Brain - Cerebellar Hemisphere26.61
- Esophagus - Gastroesophageal Junction25.4
And 29 more, listed on the interactive page.
- GO:0006357
- GO:0010971
- GO:0032968
- GO:0043123
- GO:0045893
- GO:0045944
- GO:0050727
- GO:0000794
- GO:0005634
- GO:0005654
- GO:0005694
- GO:0000976
- GO:0002039
- GO:0003682
- GO:0003712
- GO:0003713
- GO:0005515
- GO:0008353
- GO:0019899
- GO:0099122
- GO:0106140
- GO:0140008
- GO:0140011
- GO:0140012
- GO:0140046
- GO:0140055
- GO:0140072
- GO:0140119
Gastrointestinal toxicity observed in rats
Effects
- Inhibition/Decrease/Downregulation
Studies
- preclinical
Biological samples
- GI
PubMed 38773351
Related records
Trials (375)
- A Cross-over Study to Evaluate the Effect of Itraconazole and Rifampicin on the Pharmacokinetics (PK) of GSK525762 in Healthy Female Subjects of Non Child Bearing Potential
- A Dose Escalation Study to Investigate the Safety, Pharmacokinetics (PK), Pharmacodynamics (PD) and Clinical Activity of GSK525762 in Subjects With Relapsed, Refractory Hematologic Malignancies
- A Dose Escalation Study to Investigate the Safety, Pharmacokinetics (PK), Pharmacodynamics (PD), and Clinical Activity of GSK525762 Plus Trametinib in Subjects With Solid Tumors
- A Dose Exploration Study With Birabresib (MK-8628) in Participants With Selected Advanced Solid Tumors (MK-8628-006)
- A Dose Exploration Study With Birabresib (MK-8628) in Participants With Selected Hematologic Malignancies (MK-8628-005)
- A Dose-escalation Study of the Safety and Tolerability of Orally Administered TG101348 in Patients With Myelofibrosis
- A Dose-finding Study of Birabresib (MK-8628) in Participants With Recurrent Glioblastoma Multiforme (MK-8628-002)
- A Dose-Finding Study of Birabresib (MK-8628), a Small Molecule Inhibitor of the Bromodomain and Extra-Terminal (BET) Proteins, in Adults With Selected Advanced Solid Tumors (MK-8628-003)
- A Dose-finding Study of the Bromodomain (Brd) Inhibitor OTX015/ Birabresib (MK-8628) in Hematologic Malignancies (MK-8628-001)
- A Drug-drug Interaction Study to Assess the Effect of Phenytoin and Itraconazole on the Pharmacokinetics of Pelabresib in Healthy Participants
- A Drug-drug Interaction Study to Evaluate the Effects of Pelabresib on the Pharmacokinetics of Repaglinide, Midazolam, and Combined Oral Contraceptive in Patients With Advanced Malignancies
- A Drug-Food Interaction Study Between Colchicine and Grapefruit Juice
- A Long-Term Study of the Effects of Orally Administered SAR302503 in Patients With Myelofibrosis
- A Ph2, Colchicine For Inflammatory Carotid Injury And Disease Evolution After Radiotherapy
- A Pharmacokinetic Study of Colchicine With an Oral Contraceptive
- A Pharmacokinetics and Tolerability Study of Fedratinib in Subjects With Moderate and Severe Hepatic Impairment
- A Phase 1 Study Evaluating CPI-0610 in Patients With Previously Treated Multiple Myeloma
- A Phase 1 Study Evaluating CPI-0610 in Patients With Progressive Lymphoma
- A Phase 1/2 Study of CPI-0610 With and Without Ruxolitinib in Patients With Hematologic and Myeloproliferative Malignancies
- A Phase 3 Study of Pelabresib (DAK539) and Ruxolitinib in Myelofibrosis (MF)
Drugs (16)
- Amredobresib
- Apabetalone Bromodomain and extra-terminal motif (BET) inhibitor
- BI-2536
- Birabresib Bromodomain and extra-terminal motif (BET) inhibitor
- Colchicine
- Ezobresib Bromodomain and extra-terminal motif (BET) inhibitor
- Fedratinib
- GSK1210151A
- GW841819X
- LY-294002
- Methylpyrrolidone
- Mivebresib
- Molibresib Bromodomain and extra-terminal motif (BET) inhibitor
- Molibresib besylate Bromodomain and extra-terminal motif (BET) inhibitor
- Pelabresib Bromodomain and extra-terminal motif (BET) inhibitor
- RO-6870810 Bromodomain and extra-terminal motif (BET) inhibitor